Cancer Vaccine Russia
Russia claims its cancer vaccine Enteromix has shown 100% efficacy and safety in pre-clinical trials.
The vaccine is mRNA-based.
According to reports, the last three of the years dedicated to doing mandatory preclinical studies.
The vaccine’s first target cancer type is colorectal cancer.
Media reports also mention tumour size reduction of 60-80% in some conditions, increased survival, depending on disease characteristics.
Some reports claim “100% efficacy,” but these claims are not yet verified by independent or peer‐reviewed sources.
Experts caution that “preclinical efficacy” (often in animal models) does not guarantee human results.
The vaccine would be made free for patients after approval, according to claims.
The Russia vaccine is not yet in human clinical trials or widely approved—for now its status is preclinical or early trials.
The announcement was made at or around the Eastern Economic Forum in Vladivostok.
There is skepticism from international scientists about the robustness of the available data.
Uncertainty remains about safety across multiple doses and over long time time, despite claims of safety even with repeated administration.
The broader implication is hopeful—if validated, this could be a breakthrough in cancer treatment using immunotherapy/vaccine approach.
But much depends on future human trials, peer review, regulatory approval, and transparent publication of data.
Click Here